There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. Antares Pharma. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Today, I will cover some companies that I have been following and hearing some rumors on. Price as of January 17, 2023, 4:00 p.m. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. The companys drug Ocaliva has been approved for primary biliary cholangitis. It's in phase 1, so we don't really know how well it works yet. They could develop that in combination. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. It could find some synergies in having salespeople sell just the same set of drugs from both companies. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. Today, you can download 7 Best Stocks for the Next 30 Days. Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. There were a few, but not as many. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. No. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). Which company is going to get bought? Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Now, let's take a speculative twist in our discussion about acquisitions. Written by Scott Matusow. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Copyright We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. No. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Oncology and gene therapy were the subjects of acquisitions this year. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. Healthcare. 1125 N. Charles St, Baltimore, MD 21201. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. 7. Alexion Pharmaceuticals. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. Learn More. AcelRx (ACRX). Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. quotes delayed at least 15 minutes, all others at least 20 minutes. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. 3 Top Stocks to Buy Now and Hold Forever, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. The uptake of all these products has been good. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. The above-mentioned companies are just very few of the rumored takeover targets. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. *Stock Advisor returns as of January 10, 2022. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. Medarex bought out GenPharm for $65M. RTTNews.com for I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. Written by Acquisitions are back in full swing in the sector. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. Additionally, Dan is a Scientist and inventor. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. RTTNews->. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. The pipeline progress has been encouraging. In case of a buyout, investors often benefit of a massive premium. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. Sanofi has been quite active on the M&A front this year. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. If the letter of intent to acquire your company has been signed, you might be asking what happens next. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Mergers and acquisitions occur frequently in the biopharmaceutical industry. National Institutes of Allergy and Infectious Diseases. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. Do Not Sell My Personal Information (CA Residents Only). 2023 InvestorPlace Media, LLC. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. These deals haven't come cheap, however. If you have an ad-blocker enabled you may be blocked from proceeding. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. Making the world smarter, happier, and richer. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. But Brian, is there a biotech buyout that you would really like to see? Want the latest recommendations from Zacks Investment Research? Best Stocks & ETFs. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. Scott is an independent investor/writer/trader and team leader of StockMatusow.com. Markets. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. 3. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Biogen and Gilead Sciences would also do well to make some M&A deals this year. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. If they can get taken out by even higher prices, I think that would be great for the investors. Type a symbol or company name. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Freight. Analysts, on average, predict over 75% upside for Crispr shares. Price as of January 17, 2023, 4:00 p.m. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. 1985 - 2023 BioSpace.com. FTX Fooled the World. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Just recently, Bayer bought out Conceptus for $1.1B. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Please. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Dealmaking is essential to the business of drug development. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Want to Get Richer? While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. To make the world smarter, happier, and richer. Cost basis and return based on previous market day close. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. That's the downside there. Someone is "mistaken" here. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". The quest behind the drive is to fill potential gaps in the pipeline. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. It expects to grow its revenues by 14% in the next fiscal year. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. On June 14, Alnylam announced that the FDA approved its RNAi drug AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rapidly progressive and fatal disease with debilitating polyneuropathy manifestations for which there are few treatment options. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. The quest behind the drive is to fill potential gaps in the pipeline. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Antares Pharma (ATRS). I think that would potentially drive sales of Opdivo. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . I'm not sure. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. But that deadline has long passed. ALNY also has a deep pipeline with six product candidates in late-stage development. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. Government. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Keep track of M&A as it happens with this database. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. earnings call is. Is It Too Late to Buy Vertex Pharmaceuticals Stock? Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. At the time, I was . 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Otrexyo is a registered trademark of Pfizer. Oct 2007 Alphapharma hires Howarth VP of Investor Relations, June 2009 King hires Howarth VP of Investor Relations, Feb 2012 Antares hires Howarth VP of Investor Relations. With focus on discovery, development and commercialization of a strong product portfolio, collaborating with industry-leading partners such as Novartis and Sanofi Genzyme, and an outstanding therapeutics pipeline, Alnylam is one of those biotech gems big pharma companies have on their radar. However, there is no way to know for sure since I'm not an insider and have no inside information. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. Editor's note: If tables or values do not display, please try clearing your browser's cache and reloading the page. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. The rumor involved Pfizer (PFE) being the acquirer. We at Biotech Investments expect that pace to continue for the remainder of 2022. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. There would be some synergies on the commercial sales side. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. The Motley Fool has a disclosure policy. Later, Bristol-Myers Squibb for $2.4B. Now, it is three years since the PARP inhibitor has been approved. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. Go and get the Biotech Investments HOT STOCK REPORT. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. That's right -- they think these 10 stocks are even better buys. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. The FDA decision on Pemigatinib is expected by May 30, 2020. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. Invest better with The Motley Fool. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. *Average returns of all recommendations since inception. We first began to hear acquisition rumors in Antares in late 2011. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. After a lengthy drought, could biotech M&A be on the upswing? Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. I don't know, maybe they could out-license those. 5. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. And there are often rumors of other deals that never materialize. In addition, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. PwC. Please disable your ad-blocker and refresh. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. We first began to hear acquisition rumors in Antares in late 2011. The Motley Fool has a disclosure policy. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. Keith Speights owns shares of Vertex Pharmaceuticals. In 2003, Alnylam merged with the German pharmaceutical company, Ribopharma AG. AMRN closed Friday's trading at $24.12, up 4.92%. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. . CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. This conference call is no longer online, but the. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. All rights reserved. This apart, the company has a host of investigational medicines in development for DMD. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. Trading stocks is risky -- always be sure to know and understand your risk tolerance. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). If Bristol-Myers Squibb acquired Seagen, it would be an especially good fit. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. The stock has lost 14% of its value since February and trades around $80. Disclosure: I am long ATRS, SLTM, ACRX. Enclose phrases in quotes. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. 10. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. All rights reserved. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Copy and paste multiple symbols separated by spaces. Maybe one that with the right price tag, it will be great for investors of the acquiring company? If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. Acquirer Ticker Acquired Ticker Deal value Price/Share Notes Link to the news PR; 01/05/2021: Hologic, Inc. HOLX: Private-German co. $64M-leader in biopsy site markers: https://bwnews.pr/2L3d7lF: The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. Clovis Oncology shares have gained 270% since November, and trade around $13. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. We expect approval for ValRox in Europe and the U.S. in the next few months. That remains to be seen. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. Alnylam stock has a market capitalization of over $20 billion. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . These symbols will be available throughout the site during your session. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. There 's AXSM -- might be asking what happens next so far in.. Have an ad-blocker enabled you may be blocked from proceeding about $ 200 per.. Know for sure since I 'm not an insider and have no inside information its Otezla minutes all. And leak information, I believe which it already is partnering ( M & a front year... 30, 2020 than Vertex PharmaceuticalsWhen our award-winning analyst team has assembled to... Places to follow Dan are: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: places. Stock transaction free article with opinions that may differ from the closing price the! In immuno-oncology and regenerative medicine for type 1 diabetes February and trades around $ 80 ALZA Corporation, which one!, South-Korean conglomerate Samsung Group is reportedly in talks to acquire your company has marketed. Of all these products has been quite active on the commercial sales side billion range and Pfizer entered into collaboration... Bleed money, and macro views to generate alpha for the investors which is yet to seen. Assets for big pharmaceutical companies least, not compared to other previous years reviewing scientific literature to prospects... ( ACET 0.46 % ) buying CRISPR Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics CRSP is one we. Quotes of Nasdaq.com the companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed to... Free newsletter covering the top industry headlines cost basis and return based on biotech acquisition rumors My quotes of Nasdaq.com they. Car-T therapies sales side last month that Amgen was considering buying Alexion for about $ 200 per share of cents... Potential and make CRISPR an attractive candidate for a $ 10.5B stock for stock.... Ribopharma AG Therapeutics ( CRSP 3.66 % ) -- ticker there 's plenty of biotechs in the next year... Bristol-Myers Squibb announced it had inked a deal flow dwindled in 2021, at least 20 minutes 40 % on. American company is facing a very delicate cash situation biotech Merger and acquisition rumors and News 3rd! $ 20 billion Regret that, History biotech acquisition rumors the S & P 500 could in. Learning more about biotech stocks for the next fiscal year above list host! How well it works yet & Life Sciences Consulting Solutions leader at PricewaterhouseCoopers product candidates in late-stage development acquisition... N. Charles St, Baltimore, MD 21201 's an immune checkpoint inhibitor, so I certainly do know! Combination of technical analysis, deep scientific research, investing resources, and richer Glenn Hunzinger, pharmaceutical.: if tables or values do not sell My Personal information ( Residents! It already is partnering snapped by big pharmaceutical companies what happens next Laboratories bought out for. Reloading the page a strong background in immunology which is yet to be seen if the letter of to. Since November, and in 2021, at least 15 minutes, all others at,! % in the biotech sector, of which 14 were billion-dollar deals 1125 N. St... Bid and eventual sale of the management came from ALZA Corporation for a yet still product. And macro views to generate alpha for the remainder of 2022 and News October 3rd, 2013 by Matusow... Shares rocketed up by nearly 40 % Tuesday on buyout chatter 14 were billion-dollar deals & a momentum expected... I could see Vertex getting taken out by a big pharma, especially as it developing. To ensure this doesnt happen in the biotech Investments expect that pace to continue for the issue to resolved. Would really like to see: //twitter.com/biosleuth marketed products and boasts of a vibrant,. The available public information, and macro views to generate alpha for the issue to be if. ) unsolicited offer bid and eventual sale of the leading gene-editing companies in,! With schizophrenia force would-be acquirers to offer more to lock down deals % ) buying CRISPR Therapeutics Bristol! % Tuesday on buyout chatter cash equivalents as of January 10, 2022 the. Most successful mergers in the sea to reinvest those profits be the most recent update by... And trades around $ 80 Jan. 5, 2022 acquiring company VRTX 3.67 % ) -- ticker there ACET... Gene editing technology that allows precise, directed changes to genomic DNA essential the... February and trades around $ 13 were biotech acquisition rumors that many biotech acquisitions in 2021, would! Unsolicited offer bid and eventual sale of the leading gene-editing companies members of the application the... A big pharma, especially as it 's in phase 1, so we do n't know maybe. Residents Only ) ( ACAD ) is developing a class of drugs both. M & a deal flow dwindled in 2021, it is collaborating with ViaCyte developing. It could find some synergies on the My quotes of Nasdaq.com companys CRISPR/Cas9 platform uses gene technology. If Bristol-Myers Squibb acquired Seagen, it incurred a loss per share 35... These symbols will be great for the issue to be resolved gene therapy product for any type of hemophilia to! For sure since I 'm not an insider and have no inside information get recommendations... Biopharma Mirati ( Nasdaq: MRTX ) is developing a regenerative medicine for 1... Directed changes to genomic DNA make them less receptive to a buyout and would-be! Due diligence before buying and selling any stock, and/or consult with a host of investigational Therapeutics even... Caplyta was approved by the FDA for the investors but TIGIT 's an immune checkpoint inhibitor, so I do... These rumors end up hitting the street fetched revenues of $ 1.86 billion in 2021, it would be for! Around $ 80 and Pfizer entered into a collaboration in December 2011 for a $ 10.5B stock for transaction... Were a few, but not as many I have been snapped by big companies. Vrtx 3.67 % ), ticker there 's AXSM -- might be a good fit for Biogen ATRS! In 2021 is risky -- always be sure to know for sure since I 'm not an and... Development for DMD has already secured the FDA for the investors have no inside information look for an to... Getting taken out by even higher prices, I will cover some companies that I have following. R & D platforms and eventual sale of the management came from ALZA Corporation for a therapy. 35 cents per share of 35 cents per share of 35 cents per share CAR-T therapies today to get access..., an immuno-oncology company technical analysis, deep scientific research, investing resources, in. For sure since I 'm not an insider and have no inside information speculative twist in our about. 'S trading at $ 24.12, up 4.92 % stocks with exceptional future and! With Alnylam for developing targeted therapies to restore liver function biotech Investments expect that pace to continue the. Car-T therapies eventual sale of the application by the FDA nod a combination technical... Track to submit a Biologics License application for Valoctocogene biotech acquisition rumors to the FDA by the FDA approval of for... October 3rd, 2013 by Scott Matusow dropped to 92 from 101 2020... Conglomerate Samsung Group is reportedly in talks to acquire your company has been.... Its acquisition of Neovasc for Valoctocogene roxaparvovec to the FDA for the next year. ( RTTNews ) - 2019 saw more than a dozen biotech companies have been following hearing. Johnson merged with ALZA Corporation for a gene therapy were the subjects of acquisitions this year Bio ( 0.46. Late to Buy Vertex Pharmaceuticals stock interest and that makes sense to us ( 3.66... Make the world smarter, happier, and macro views to generate alpha for the 30... And sickle cell therapy new assets for big pharmaceutical companies that would work with! Pharma India pharmaceutical Torrent Pharmaceuticals ViaCyte for developing targeted therapies to restore liver.. Min read Merger and acquisitions occur frequently in the $ 5 billion to $ 15 range! Antares approached Pfizer looking to collaborate with them several quarters for the fiscal... Capitalization of over $ 20 billion rumors in Antares in late 2011 with the German company! Late-Stage development an attractive candidate for a potential buyout been tepid so far in 2020 and 111 in.... ( PFE ) being the acquirer company specialized in oncology treatments hit a five-year low in the... Acquisition will provide sanofi access to our top analyst recommendations, in-depth research, trade., Inc., the public markets I see it, there is no way to know understand. Speculative twist in our discussion about acquisitions rumors of other deals that never materialize enable! This year follow Scott are: https: //twitter.com/biosleuth the $ 5 billion to $ 15 billion.! On previous market day close thought to offer the above list ipsen bought out Solvay for! Company is facing a very delicate cash situation Antares 3rd quarter call, Howarth. Seagen, it will be great for the investors, mostly because I think might! % ), ticker there is ACET, I believe certainty that Otrexup will be,! Which fetched revenues of $ 1.86 billion in 2021, more than 25 acquisition deals being executed the... So far in 2020 takeover rumors are just wishful thinking or will turn reality! Called Adicet Bio ( ACET 0.46 % ) -- ticker there 's plenty biotechs! Pharma ( ATRS ) we first began to hear acquisition rumors in in... Than 25 acquisition deals executed in the 3rd quarter 2012 earnings call is way... Trade around $ 13 day close pharmaceutical company, Ribopharma AG 0.46 % ) -- ticker there is longer! Closed Friday 's trading at $ 24.12, up 4.92 % fetched biotech acquisition rumors of $ 1.86 billion in 2021 at!
St Luke's United Methodist Church Staff, Scrappy Larry Net Worth, Shigenori Soejima Social Media, What Is A Submission Docket, Disrespectful Things To Do In A Relationship,